de Groot FM - Search Results

1

"Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core.

de Groot FM, Albrecht C, Koekkoek R, Beusker PH, Scheeren HW. de Groot FM, et al. Angew Chem Int Ed Engl. 2003 Sep 29;42(37):4490-4. doi: 10.1002/anie.200351942. Angew Chem Int Ed Engl. 2003. PMID: 14520746 No abstract available.

2

Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue.

Damen EW, Nevalainen TJ, van den Bergh TJ, de Groot FM, Scheeren HW. Damen EW, et al. Among authors: de groot fm. Bioorg Med Chem. 2002 Jan;10(1):71-7. doi: 10.1016/s0968-0896(01)00235-8. Bioorg Med Chem. 2002. PMID: 11738608

3

Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.

de Groot FM, van Berkom LW, Scheeren HW. de Groot FM, et al. J Med Chem. 2000 Aug 10;43(16):3093-102. doi: 10.1021/jm0009078. J Med Chem. 2000. PMID: 10956217

4

Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.

de Groot FM, Loos WJ, Koekkoek R, van Berkom LW, Busscher GF, Seelen AE, Albrecht C, de Bruijn P, Scheeren HW. de Groot FM, et al. Among authors: de bruijn p. J Org Chem. 2001 Dec 28;66(26):8815-30. doi: 10.1021/jo0158884. J Org Chem. 2001. PMID: 11749612

5

Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.

de Groot FM, Broxterman HJ, Adams HP, van Vliet A, Tesser GI, Elderkamp YW, Schraa AJ, Kok RJ, Molema G, Pinedo HM, Scheeren HW. de Groot FM, et al. Mol Cancer Ther. 2002 Sep;1(11):901-11. Mol Cancer Ther. 2002. PMID: 12481411

6

Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.

de Groot FM, de Bart AC, Verheijen JH, Scheeren HW. de Groot FM, et al. Among authors: de bart ac. J Med Chem. 1999 Dec 16;42(25):5277-83. doi: 10.1021/jm9910472. J Med Chem. 1999. PMID: 10602713

7

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.

de Groot FM, Damen EW, Scheeren HW. de Groot FM, et al. Curr Med Chem. 2001 Jul;8(9):1093-122. doi: 10.2174/0929867013372634. Curr Med Chem. 2001. PMID: 11472243 Review.

8

Semisynthesis of Some 7-Deoxypaclitaxel Analogs from Taxine B.

Wiegerinck PH, Fluks L, Hammink JB, Mulders SJ, de Groot FM, van Rozendaal HL, Scheeren HW. Wiegerinck PH, et al. Among authors: de groot fm. J Org Chem. 1996 Oct 4;61(20):7092-7100. doi: 10.1021/jo960438a. J Org Chem. 1996. PMID: 11667611

9

Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin.

de Groot FM, Busscher GF, Aben RW, Scheeren HW. de Groot FM, et al. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2371-6. doi: 10.1016/s0960-894x(02)00388-8. Bioorg Med Chem Lett. 2002. PMID: 12161136

10

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A. Devy L, et al. Among authors: de groot fm. FASEB J. 2004 Mar;18(3):565-7. doi: 10.1096/fj.03-0462fje. Epub 2004 Jan 20. FASEB J. 2004. PMID: 14734647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters